NewAmsterdam Pharma (NAMS) Net Income (2023 - 2026)
NewAmsterdam Pharma (NAMS) reported Net Income of -$48.4 million for Q1 2026, down 22.55% on a YoY basis from -$62.5 million in Q1 2025, and up 35.35% sequentially from -$74.9 million in Q4 2025.
NewAmsterdam Pharma (NAMS) Net Income (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma (NAMS) has 4 years of Net Income data on file, last reported at -$48.4 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income fell 22.55% year-over-year to -$48.4 million; the trailing twelve-month figure through Mar 2026 stood at -$212.7 million (down 13.54% YoY), and the FY2025 full-year result was -$202.5 million, up 16.18% from the prior year.
- Net Income grew to -$48.4 million in Q1 2026, from -$74.9 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $58.1 million in Q4 2023 to a low of -$93.8 million in Q1 2024.
- A 4-year average of -$43.7 million and a median of -$44.6 million in 2023 frame the typical range for Net Income.
- Across the five-year window, Net Income soared 64.68% in 2024 and sank 332.54% in 2025, its largest moves.
- Tracing NAMS's Net Income over 4 years: stood at $58.1 million in 2023, then slumped by 258.69% to -$92.2 million in 2024, then climbed by 18.72% to -$74.9 million in 2025, then surged by 35.35% to -$48.4 million in 2026.
- Business Quant data shows NAMS's Net Income at -$48.4 million in Q1 2026, -$74.9 million in Q4 2025, and -$72.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | NewAmsterdam Pharma | 3.72 Bn | 3.72 Bn | - | -48.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.44 Mn |
| Dec 31, 2025 | -74.92 Mn |
| Sep 30, 2025 | -72.01 Mn |
| Jun 30, 2025 | -17.36 Mn |
| Mar 31, 2025 | -39.53 Mn |
| Dec 31, 2024 | -92.18 Mn |
| Sep 30, 2024 | -16.65 Mn |
| Jun 30, 2024 | -39.01 Mn |
| Mar 31, 2024 | -93.77 Mn |
| Dec 31, 2023 | 58.09 Mn |
| Sep 30, 2023 | -47.13 Mn |
| Mar 31, 2023 | -42.02 Mn |